Intellia Therapeutics Inc Stock News

NEW YORK , July 2, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Intellia Therapeutics, Inc. (NASDAQ: NTLA) breac

Wood added to her positions in Palantir, Archer Aviation, and Intellia Therapeutics on Monday. Palantir is one of her largest holdings, and the big data analytics specialist has more than quadrupled s

Searching for quality undiscovered biotech stocks can be a bit like a treasure hunt. The biotech scene is full of intriguing innovators trying to progress their treatments through various clinical tri

With the progression of modern medicine, and the continuous discoveries in the realm of gene editing, investing early in the technology could be a game changer for long-term returns if selecting the b

3 Biotech Stocks For The Second Half Of 2024

Intellia (NTLA) appoints Edward Dulac as its new chief financial officer after Glenn Goddard steps down from his role with effect from Jun 30.

Gene editing is a game-changer. With it, we can remove cells from your body, edit them, and then reintroduce them back into the body.

CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera

CAMBRIDGE, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera

Gene-editing stocks has been gaining substantial attention, as the industry holds the potential to revolutionize medicine. From curing genetic disorders to enhancing agricultural productivity, the app

Biotech stocks are high-risk, high-return opportunities that are under the mercy of several make-or-break catalysts, most of which are binary events. It pays to remain cognizant of the timing of these

Investors looking for long-term returns should consider investing in strong buy Cathie Wood stocks this month. The ARK Invest Chief Executive Officer (CEO) gained a massive following in 2020 after all

- Data to offer insight into the safety and pharmacodynamics of redosing patients with a systemically delivered LNP-based CRISPR gene editing candidate - Data to offer insight into the safety and phar

Intellia's (NTLA) lead genome-editing candidate, NTLA-2001 being developed to treat transthyretin (ATTR) amyloidosis, holds promise. Other pipeline candidates are also progressing well.

CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera